Atlas Genetics is creating a new category of in vitro diagnostics designed for decentralized Point-of-Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-to-use, rapid and cost-effective solution for on-demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases.
Atlas Genetics has raised approximately £63m to date from a strong investor base. The last financing raised was £28m ($35m) Series D (2016) raised from a syndicate including all Series C investors, Novartis Venture Funds, Johnson & Johnson Development Corporation, LSP (Life Science Partners), BB Biotech Ventures, Consort Medical plc, Technology Venture Partners, RMI Partners and private investors, plus Chinese biotechnology company, Wondfo Biotech.
Atlas Genetics has been awarded grant funding from the South West Regional Development Agency (SWRDA), The Wellcome Trust, the United States Institutes of Health, and a £1.6m project from The Technology Strategy Board, in partnership with Public Health England and £2m from Innovate UK as part of the Small Business Research Initiative.
Atlas Genetics is engaged in a number of collaborative projects with major diagnostic and pharmaceutical companies, and various public bodies. We aim to utilise Atlas Genetics’ technology in specific applications outside of the Company’s core product area of STIs to expand the utility of the io® platform.